This was comparable to the IC50 observed when a version of the FR6_1 catalyst targeting KRAS G12D mRNA was transfected into RKO colon carcinoma cells (60 pmol/106 cells)31, although in both cases, the final effective concentration of XNAzyme(s) inside cells was unknown. The gene discussed is KRAS; the disease is colon carcinoma.